News Agency
Men's Weekly

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's disease trial and interim analysis timeline

  • Written by PR Newswire
Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's disease trial and interim analysis timeline

Interim analysis planned for January 2026 with final trial results in late 2026

Highlights:

  • With the 100th participant enrolled in the XanaMIA trial, the timeline for the planned interim analysis is confirmed for January 2026 and the timeline for final results reconfirmed for late 2026
  • An independent Data Monitoring Committee will review all...

Read more: Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's disease trial and interim...

How Headless CMS Enhances Responsive Design and Layout Flexibility

Image by freepik As digital technology continues to evolve at a breakneck pace, users expect much more from content than ever before, and responsive design is crucial to ensure content not only looks but operates across all screens. No longer are... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion